Notice Number: NOT-OD-07-081
Key Dates
Release Date: August 2, 2007
Contract Proposal Receipt Date: November 5, 2007 at 5:00 PM Eastern Time
Issued by
National Institutes of Health (NIH), (http://www.nih.gov)
Centers
for Disease Control and Prevention (CDC), (http://www.cdc.gov)
The purpose of this notice is to inform the small business research community and potential research institution partners of the release of the Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals (PHS 2008-1.) Eligible small businesses with the capability to conduct research and development (R&D) in any of the health related topic areas described in PHS 2008-1, and to commercialize the results of that R&D, are invited to submit contract proposals. Proposals must be received by 5:00 PM Eastern Time, November 5, 2007.
Objectives of the SBIR program include stimulating technological innovation in the private sector, strengthening the role of small business in meeting Federal R/R&D needs, increasing private sector commercialization of innovations developed through Federal SBIR R&D, increasing small business participation in Federal R&D, and fostering and encouraging participation by socially and economically disadvantaged small business concerns and women-owned small business concerns in the SBIR program.
The SBIR program consists of the following three phases:
Phase I: The objective of this phase is to determine the scientific or technical feasibility and commercial merit of the proposed research or R&D efforts and the quality of performance of the small business concern, prior to providing further Federal support in Phase II. Unless otherwise specified in the topic, Phase I awards normally may not exceed $100,000 for direct costs, indirect costs, and profit (fixed fee) for a period normally not to exceed 6 months.
Phase II: The objective of this phase is to continue the research or R&D efforts initiated in Phase I. Funding shall be based on the results of Phase I and the scientific and technical merit and commercial potential of the Phase II proposal. Unless otherwise specified by the awarding component, Phase II awards normally may not exceed $750,000 for direct costs, indirect costs, and profit (fixed fee) for a period normally not to exceed two years. Phase II proposals may only be submitted by firms awarded Phase I contracts, and only upon the request of the Contracting Officer, if not submitted concurrently with the initial Phase I proposal under the Fast-Track procedure described in the solicitation.
The Fast-Track option is an opportunity for small business concerns to submit both a Phase I and Phase II proposal for concurrent peer review. This option also has the potential to minimize any funding gap between Phase I and Phase II. Proposals must be prepared in accordance with Phase I and Phase II proposal preparation instructions. Fast-Track is applicable only to proposals submitted to the NIH and only if an awarding component indicates in the solicitation that it is accepting Fast-Track proposals for a particular topic.
Phase III: The objective of this phase is for the small business concern to pursue with non-SBIR funds the commercialization objectives resulting from the outcomes of the research or R&D funded in Phases I and II. Phase III may involve follow-on, non-SBIR funded R&D or production contracts for products or processes intended for use by the U.S. Government.
In accord with the intent of the SBIR program to increase private sector commercialization of innovations derived from Federal R&D, scientists at research institutions can play an important role in an SBIR project by serving as consultants and/or subcontractors to the small business concern. Generally, one-third of the Phase I budget may be spent on consultant and/or subcontractual costs, and, generally, one-half of the Phase II budget may be spent on such costs. In this manner, a small business concern with limited expertise and/or research facilities may benefit from teaming with a scientist(s) at a research institution.
NIH has implemented a policy to allow more than one Project Director/Principal Investigator (PD/PI) on research projects, including SBIR awards. The policy offers new approaches to maximize the potential of team science efforts. The multiple Principal Investigator (PI) model will supplement, and not replace, the traditional single Principal Investigator (PI) model. Specific information about the multiple PD/PI option is included in the PHS 2008-1 Contract Solicitation.
Eligibility requirements, definitions, submission procedures, review considerations, contract proposal forms and instructions, and other pertinent information are contained in the Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals (PHS 2008-1). See SBIR Phase I Contract Solicitation PHS 2008-1.
Potential offerors are encouraged to check the NIH Small Business Funding Opportunities Web site for updates on the program. The Web site offers electronic access to SBIR solicitations, abstracts of ongoing SBIR projects, the latest updates on the SBIR program, hyperlinks to sources of business assistance, and other useful information. Any updates or corrections to the contract solicitation will be posted there.
Note: The SBIR Phase I Contract Solicitation will only be available via electronic means; however, submissions of contract proposals remain in paper form. Be sure to use the appropriate CONTRACT proposal forms as they differ from the SF424 (R&R) SBIR GRANT application forms.
Following are the research topics contained in the Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals (PHS 2008-1) for the contract proposal receipt date of NOVEMBER 5, 2007:
| NATIONAL INSTITUTES OF HEALTH | |
| National Cancer Institute (NCI) | |
| 229 | Development of Molecular Pharmacodynamic Assays for Targeted Therapies |
| 236 | Antibody Array for Cancer Detection |
| 241 | Multifunctional Therapeutics Based on Nanotechnology |
| 242 | Biosensors for Early Cancer Detection and Risk Assessment |
| 243 | Novel and Improved Methods to Measure Cancer Epigenetic Biomarkers |
| 244 | High-Throughput Assays for Isolation and Characterization of Cancer Stem Cells |
| 245 | Assay Systems for Drug Efficacy Using Cancer Stem Cells |
| 246 | Integrating Patient-Reported Outcomes in Hospice and Palliative Care Practices |
| 247 | Portable e-Technology Diet and Physical Activity Tools for Consumers |
| 248 | Patient-Centered Coordinated Cancer Care System |
| 249 | System to Analyze and Support Biomarker Research and Development Strategies |
| 250 | Biopsy Instruments and Devices that Preserve Molecular Profiles in Tumors |
| 251 | Development of Anti-Cancer Agents |
| 252 | Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer |
| 253 | Advances in Protein Expression of Post-Translationally Modified Cancer Related Proteins |
| 254 | Development of Clinical Quantitative Multiplex High-Throughput Mass Spectrometric Immunoassay for Detecting Low Abundance Cancer Related Proteins/Peptides in Bodily Fluids |
| National Heart, Lung, and Blood Institute (NHLBI) | |
| 038 | Production of Generic Modified Hemoglobin |
| 039 | Aged Animal Resources for Cardiovascular Disease Research |
| 040 | Nanoprobes for Non-Invasive Detection of Atherosclerotic Plaques |
| 041 | Cardiovascular, Lung, And Blood Computational Model Library |
| 042 | Refinement and Standardization of a Parvovirus B19 Vaccine |
| 043 | Development of Pathogen Inactivation Technologies for Blood Components |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | |
| 030 | Alcohol Biosensors and Data Analysis Systems |
| 031 | Biomarkers for Alcohol-Induced Disorders |
| 032 | Medications Development to Treat Alcohol Use Disorders and Alcohol Related Medical Disorders |
| 033 | Development of Methodology for Measuring and Enhancing Compliance for Medications |
| National Institute on Drug Abuse (NIDA) | |
| 090 | Develop a Real-Time fMRI Feedback System that Allows Drug Abusers to Control their Cravings and Urges and/or Increase their Self-Control of their Drug Taking |
| 091 | Design and Synthesis of Treatment Agents for Drug Abuse |
| 093 | Development of Website Training on Addiction Medicine for Pain Management Providers |
| 094 | Development of Web-based Skills Training for Primary Care Physicians on Screening, Brief Intervention, Referral and Treatment |
| 095 | Drug Abuse Screening, Assessment, Patient-Treatment Matching Technologies for Use in Primary Care |
| 096 | Tools to Measure Intervention Costs, Cost Effectiveness, and Net Economic Benefits |
| 097 | Development of Nanoscience-based Probes, Delivery Systems, and Therapies for Substance Use Disorders |
| 098 | Discovery and Study of Psychoactive Components of Botanicals |
| National Institute of Mental Health (NIMH) | |
| 059 | Development and Evaluation of Tools to Enhance the Dissemination of Educational Information Intended Specifically for Autism Caregivers |
| 060 | Multi-Media Training for Social Workers in Evidence-Based Mental Health Practices and Psychotherapies |
| CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) | |
| National Center on Birth Defects and Developmental Disabilities (NCBDDD) | |
| 007 | Maximize Quality and Quantity of DNA from Mailed Cytobrushes |
| Coordinating Office for Terrorism Preparedness and Emergency Response (COTPER) | |
| 001 | Environmental Monitoring Systems for Forward Placed Assets |
| Immunization Safety Office (ISO) | |
| 003 | Novel or Enhanced Methods for Vaccination via the Respiratory Tract |
| 004 | Novel or Enhanced Methods for Cutaneous Vaccination |
| 005 | Novel or Enhanced Methods for Vaccination by Jet Injection |
Note: Contract proposals will be accepted only if they respond specifically to a research topic within this PHS 2008-1 solicitation. Small business concerns interested in applying for a grant through the SBIR (or Small Business Technology Transfer [STTR]) programs may access these funding opportunities through the following links:
- 2007 SBIR and STTR Omnibus Solicitations of the NIH, CDC, and
FDA for SBIR and STTR Grant Applications:
- SBIR Parent Grant Funding Opportunity Announcement (PA-07-280)
- STTR Parent Grant Funding Opportunity Announcement (PA-07-281)
- SBIR/STTR Program Descriptions and Research Grant Topics
- Additional SBIR/STTR Grant Funding Opportunities are posted at http://grants.nih.gov/grants/funding/sbir_announcements.htm.
To understand better the differences between grants and contracts, see http://grants.nih.gov/grants/funding/contracts_vs_grants.htm.
Inquiries
Contracting Officers
Any small business concern that intends to submit an SBIR contract proposal under this Solicitation should provide the appropriate contracting officer(s) with early, written notice of its intent, giving its name, address, telephone, and topic number(s). If a topic is modified or canceled before this Solicitation closes, only those companies that have expressed such intent will be notified.
NATIONAL INSTITUTES OF HEALTH (NIH)
National
Cancer Institute (NCI)
Ms. Mary Landi-O Leary
Phone: (301) 435-3807
Fax: (301) 480-0309
Email: ml186r@nih.gov
National Heart, Lung, and Blood
Institute (NHLBI)
Mr. John Taylor
Phone: (301) 435-0327
Fax: (301) 480-3338
E-mail: taylorjc@nhlbi.nih.gov
National Institute on Alcohol Abuse and Alcoholism
(NIAAA)
Mr. Matthew L. Packard
Phone: (301) 443-3041
Fax: (301) 443-3891
Email:
packardm@mail.nih.gov
National Institute on Drug Abuse (NIDA)
Mr. Craig Sager
Phone: (301) 443-6677
Fax: (301) 443-7595
Email: cs591t@nih.gov
National Institute
of Mental Health (NIMH)
Ms. Suzanne Stinson
Phone: (301) 443-2696
Fax: (301)
443-0501
Email: sstinson@mail.nih.gov
CENTERS FOR DISEASE CONTROL AND PREVENTION
National Center on Birth Defects and Developmental Disabilities
(NCBDDD)
Mr. Carlos M. Smiley
Phone: (770) 488-2754
Fax: (770) 488-2777
Email:
CSmiley1@cdc.gov
Coordinating Office for Terrorism Preparedness and Emergency
Response (COTPER)
Mr. Jeffrey L. Napier
Phone: (770) 488-2628
Email: JNapier@cdc.gov
Immunization Safety Office (ISO)
Mr. Jeff Miller
Phone:
(770) 488-2651
Fax: (770) 488-2777
Email: afx2@cdc.gov
General Questions about the NIH SBIR Program:
Ms. Jo Anne Goodnight
NIH SBIR/STTR Program Coordinator
6705 Rockledge Drive
Rockledge I, Room 3540
Bethesda, MD 20892-7963
Phone:
301-435-2688
Fax: 301-480-0146
Email: sbir@od.nih.gov
Ms. Kay Etzler
NIH SBIR/STTR
Program Analyst
6705 Rockledge Drive
Rockledge I, Room 3535
Bethesda, MD 20892-7963
Phone: 301-435-2713
Fax: 301-480-0146
Email: sbir@od.nih.gov
Kathleen J. Shino,
M.B.A.
NIH SBIR/STTR Program
6705 Rockledge Drive
Rockledge I, Room 3522
Bethesda,
MD 20892
Phone: 301-435-2689,
Fax: 301-480-0146
Email: shinok@mail.nih.gov
and Human Services (HHS)
